Genetic Risk Assessment for Opioid Use Disorder

Among the many known factors associated with increased risk for opioid addiction, genetics is one of the most significant.1 But which patients may be at increased risk? AvertD™ allows you to better understand your patients’ genetic risk for OUD before a prescription is written.

Genetic Risk Assessment
for Opioid Use Disorder

Among the many known factors associated with increased risk for opioid addiction, genetics is one of the most significant.1 But which patients may be at increased risk? AvertD allows you to better understand your patients’ genetic risk for OUD before a prescription is written.

providers.affordable

AvertD Helps You Treat Acute
Pain Safely and Effectively

You want to treat your patients experiencing acute pain as safely and effectively as possible. However, when a first prescription of oral opioids is being considered, it’s important to understand that the risk of addiction is higher for some patients than others. Knowing which patients may be at increased genetic risk for Opioid Use Disorder (OUD) with AvertD can help you make more informed decisions about how to treat their acute pain.

privacy-for-patients-mobile

Genetic Risk for Opioid
Addiction Matters

Recommended by many state and medical specialty prescribing guidelines, risk assessment is likely already part of your clinical workflow and decision-making when it comes to prescribing opioids. Among the many known factors associated with increased risk for opioid addiction, genetics is one of the most significant.1 However, until now, physicians haven’t had a clinically-validated way to assess genetic risk for OUD.

Genetic Risk for Opioid
Addiction Matters

Recommended by many state and medical specialty prescribing guidelines, risk assessment is likely already part of your clinical workflow and decision-making when it comes to prescribing opioids. Among the many known factors associated with increased risk for opioid addiction, genetics is one of the most significant.1 However, until now, physicians haven’t had a clinically-validated way to assess genetic risk for OUD.

privacy-for-patients-mobile
providers.affordable

Help Your Patients
Avoid Opioid Addiction

AvertD™ is a clinically validated genetic test that tells you and your patients if they may be at increased genetic risk for OUD before a prescription is written. Requiring only a simple cheek swab sample, AvertD analyzes 15 genetic markers involved in the brain reward pathways associated with addiction to identify if a patient has a High or Low Genetic Risk for developing OUD. Easily integrated into your existing clinical workflows, AvertD provides personalized risk information to support more informed decision-making when use of oral opioids for acute pain is being considered.

NOTE: Because genetics are only one factor in understanding the risk of developing OUD from using oral opioids, AvertD test results should always be used in conjunction with a complete clinical evaluation to determine the appropriateness of oral opioids in an acute pain management plan.

AvertD Testing Is
Simple & Easy

Easy

Painless

Swab the patient’s cheek and mail the sample to our CAP-accredited and CLIA-certified lab.

Rapid

Timely

Access the patient’s test results securely online after the lab receives and processes the sample.

Clear

Informative

The AvertD results report will indicate if your patient has a High or Low Genetic Risk for Opioid Use Disorder.

Make More Informed Decisions
About Opioid Prescribing

If a patient is identified as having a High Genetic Risk, you and your patient may wish to explore alternative pain management options that minimize or avoid use of prescription oral opioids.

If a patient is identified as having a Low Genetic Risk, existing guidelines should still be followed to ensure safe and effective opioid prescribing.

providers.affordable

Clinical Performance
of the AvertD Test

AvertD was clinically validated through a blinded, multi-center, longitudinal study evaluating patients after their initial exposure to prescription oral opioids for 4 to 30 days (n=385). They were evaluated at least one year post-exposure. The study design allowed for random representative sampling mirroring adults in the U.S. prescribed oral opioids.

In the study, AvertD demonstrated 82% sensitivity and 80% specificity with no statistically significant differences in clinical performance observed based on gender, age, length of follow-up from opioid exposure, race, or ethnicity. In addition, patients with a High Genetic Risk were shown to be 16x more likely to develop OUD than patients with a Low Genetic Risk.2,3

Affordable

AvertD is Accessible and Affordable

Our goal is to offer patients the lowest cost option available to them. We are working diligently to ensure AvertD is covered by most insurance companies. Depending on the patient’s insurance, their maximum out-of-pocket cost may vary. If coverage is denied or only part of the test is covered, SOLVD Health may appeal the decision on behalf of the patient. For details about coverage, please contact the patient’s insurance company. If the patient’s insurance does not pay for the test, the patient will be billed directly for $199.

Privacy-Trust

Patient and Provider Privacy Matters

We respect your privacy and your patients’ privacy. Our lab is CAP-accredited and CLIA-certified and follows stringent medical privacy policies and practices. We adhere to the safe, secure, and HIPAA-compliant storage of all personal health information.

1Bevilacqua L, Goldman D. Genes and addictions. Clin Pharmacol Ther. 2009; 85(4):359–361. doi:10.1038/clpt.2009.6
2Donaldson K, Cardamone D, Genovese M, Garbely J, Demers L. Clinical Performance of a Gene-Based Machine Learning Classifier in Assessing Risk of Developing OUD in Subjects Taking Oral Opioids: A Prospective Observational Study. Ann Clin Lab Sci July-August 2021 vol. 51 no. 4 451-460
3
Based on an OUD prevalence of 5% in the post-surgical population